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A major weapon used by the immune system 
to combat infection is the secretion of antibody 
molecules into bodily fl  uids. Antibodies, which 
bind to and eliminate foreign antigens, repre-
sent soluble versions of the cell surface Ig pro-
teins that act as the B cell receptor for antigen 
(BCR). More than 70 yr ago, antibodies were 
found to alter their antigen-binding properties 
over the course of an immune response (1). The 
term “maturation of the immune response” was 
subsequently coined to describe the increase in 
antibody affi   nity that is now recognized to be 
a defi  ning characteristic of T cell–dependent 
(TD) humoral immune responses (2).
To secrete antibody, antigen-activated B 
cells must fi  rst diff  erentiate into plasma cells. 
During TD immune responses, plasma cells 
are initially produced in transient extrafollicu-
lar proliferative foci (3) but are subsequently 
derived from B cells participating in the follic-
ular germinal center (GC) reaction (4, 5). Evi-
dence that GCs might be connected with 
maturation of the serum antibody response 
was provided by the discovery that somatic 
hypermutation (SHM) of Ig genes occurs in 
GCs (6) and that rare mutant clones expressing 
BCRs with increased affi   nity for the immuniz-
ing antigen preferentially survive there (4, 7). 
Nevertheless, the precise factors that cause GC 
B cells to diff  erentiate into plasma cells and, 
thus, drive affi   nity maturation of the antibody 
response remain unclear (8). In vitro experi-
ments have suggested that stochastic or nonse-
lective mechanisms are of primary importance 
in the regulation of plasma cell diff  erentiation 
(9). On the other hand, indirect evidence sug-
gests that plasma cell diff   erentiation of GC 
B cells may be more selective, with only those 
cells that exceed a threshold antigen affi   nity 
contributing to the antibody response (10, 11). 
Distinguishing between these two possibilities 
has proven diffi   cult because current experi-
mental models do not allow affi   nity-based se-
lection and plasma cell diff  erentiation of GC 
B cells to be comprehensively tracked in vivo.
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A hallmark of T cell–dependent immune responses is the progressive increase in the ability of 
serum antibodies to bind antigen and provide immune protection. Affi  nity maturation of the 
antibody response is thought to be connected with the preferential survival of germinal centre 
(GC) B cells that have acquired increased affi  nity for antigen via somatic hypermutation of 
their immunoglobulin genes. However, the mechanisms that drive affi  nity maturation remain 
obscure because of the diffi  culty in tracking the affi  nity-based selection of GC B cells and 
their differentiation into plasma cells. We describe a powerful new model that allows these 
processes to be followed as they occur in vivo. In contrast to evidence from in vitro systems, 
responding GC B cells do not undergo plasma cell differentiation stochastically. Rather, only 
GC B cells that have acquired high affi  nity for the immunizing antigen form plasma cells. 
Affi  nity maturation is therefore driven by a tightly controlled mechanism that ensures only 
antibodies with the greatest possibility of neutralizing foreign antigen are produced. Because 
the body can sustain only limited numbers of plasma cells, this “quality control” over plasma 
cell differentiation is likely critical for establishing effective humoral immunity.
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The SWHEL Ig knock-in mouse model was developed to 
analyze TD B cell responses to the protein antigen hen egg 
lysozyme (HEL) conjugated to the sheep RBC (SRBC) car-
rier (12). SWHEL B cells express the anti-HEL BCR encoded 
by the high affi   nity mAb HyHEL10 and can undergo both 
class switch recombination and SHM (13). Adoptive transfer 
of small numbers of SWHEL B cells into CD45.1 congenic re-
cipients and challenge with HEL-SRBC results in a typical 
TD immune response dominated by secretion of IgG1 anti-
bodies derived from donor SWHEL B cells (12). Responding 
SWHEL B cells can be tracked with precision by virtue of their 
expression of the anti-HEL BCR and the CD45.2 allotypic 
marker. The recombinant mutant HEL protein (HEL3X) binds 
HyHEL10 with >10,000-fold lower affi   nity than wild-type 
HEL (HELWT) (14). HEL3X-SRBC triggers migration of re-
sponding SWHEL B cells into GCs but is ineff  ective at eliciting 
an extrafollicular plasma cell response (14). In this report we 
exploit the low affi   nity of HEL3X to develop a system in which 
the affi   nity-based selection of GC B cells and their diff  erentia-
tion into plasma cells can be followed. This approach revealed 
that affi   nity maturation of TD antibody responses is driven by 
a mechanism that permits only GC B cells that have acquired 
high affi   nity for antigen to diff  erentiate into plasma cells.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
When SWHEL B cells are challenged with either high affi   n-
ity (HELWT-SRBC) or low affi   nity (HEL3X-SRBC) antigen 
in CD45.1 congenic recipient mice, similar frequencies of 
donor-derived (CD45.2+) GC B cells are produced at over 
the fi  rst 15 d of the response (14), and these cells undergo 
equivalent rates of class switch recombination to IgG1 (Fig. 
1 A). The extent of SHM measured during the early stages of 
Figure 1.  GC and antibody responses to low and high affi  nity anti-
gens. SWHEL B cells were adoptively transferred into CD45.1 congenic 
mice and challenged with HELWT-SRBC, HEL3X-SRBC, or mock antigen. 
(A) Splenocytes from recipient mice were analyzed by fl  ow cytometry for 
expression of CD45.2, IgG1, and the ability to bind HELWT. The percentage 
of donor-derived HELWT-binding GC B cells that had switched to IgG1 was 
determined and plotted over the course of the response. Data points rep-
resent individual recipients, and lines connect the means. (B) Splenocytes 
from recipient mice (n = 3) were pooled and stained with CD45.2, syndecan-
1, and HELWT. Single CD45.2+, HELWT-binding, GC (syndecan-1−) B cells 
were sorted, and the targeted Ig heavy chain variable gene was PCR 
 amplifi  ed and sequenced. Points represent the frequency of somatic mu-
tations in individual clones (integers). A statistically signifi  cant difference 
in mean mutation frequency per clone (bars) was detected at day 15 and 
appeared close to signifi  cant at day 10 but was not signifi  cant at day 5. 
(C) Sera were collected from recipient mice, and the concentration of 
anti-HELWT IgG1 antibodies was measured by ELISA. Data points represent 
individual recipients, and lines connect the means. (D) Affi  nity maturation 
of the IgG1 antibody response to HEL3X-SRBC. IgG1 antibodies in pooled 
sera from recipient mice (n = 5) on day 15 of the responses to HELWT-
SRBC and HEL3X-SRBC were analyzed for their ability to bind HELWT and 
HEL3X in parallel ELISAs.JEM VOL. 203, October 30, 2006  2421
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the GC response (day 5) also does not diff  er (Fig. 1 B). How-
ever, as the responses progress, GC B cells responding to the 
lower affi   nity HEL3X-SRBC accumulate somatic mutations 
faster and by day 15 contain signifi  cantly more mutations per 
Ig heavy chain variable region gene than GC B cells respond-
ing to HELWT-SRBC (Fig. 1 B). These observations confi  rm 
previous analyses of TD antihapten responses showing similar 
rates of SHM when initial antigen affi   nity is high or low but 
enhanced selection for mutated variable regions in B cells 
with low initial antigen affi   nity (15).
SWHEL B cells challenged with HEL3X-SRBC do not 
produce the burst of extrafollicular plasma cells that typically 
peaks around day 5 of responses to higher affi   nity antigens 
such as HELWT-SRBC (14). As a result, the levels of both to-
tal anti-HEL antibody (14) and anti-HEL IgG1 (Fig. 1 C) 
present at day 5 are  100-fold lower when SWHEL B cells 
are challenged with HEL3X-SRBC compared with HELWT-
SRBC. Nevertheless, the concentration of anti-HEL IgG1 in 
recipient serum increases progressively from days 5 to 20 of 
the response to HEL3X-SRBC (Fig. 1 C). This antibody is 
derived from SWHEL donor B cells, because it is not detected 
in recipients receiving HEL3X-SRBC alone (unpublished 
data). To examine whether the antibodies elicited in response 
to HEL3X undergo affi   nity maturation, serum anti-HEL IgG1 
present at day 15 of the two responses was tested by ELISA 
for binding to HELWT and HEL3X. As expected, the IgG1 
produced in response to HELWT-SRBC bound effi   ciently to 
HELWT but showed negligible binding to HEL3X (Fig. 1 D). 
In contrast, the serum anti-HEL IgG1 from recipients chal-
lenged with HEL3X-SRBC showed almost equivalent bind-
ing to HELWT and HEL3X (Fig. 1 D), indicating that affi   nity 
maturation to HEL3X had indeed occurred.
To track the appearance and ultimate fate of GC B cells 
acquiring increased affi   nity for HEL3X, donor-derived B cells 
within the spleens of mice immunized with HEL3X-SRBC 
were stained directly with fl   uorescently labeled HEL3X at 
days 5, 10, and 15 of the response (Fig. 2). Analysis of 
CD45.2+ donor cells revealed a progressive increase in HEL3X 
binding in mice challenged with HEL3X-SRBC but not 
HELWT-SRBC (Fig. 2). When HEL3X binding was counter-
stained for surface IgG1 so that HEL3X binding by IgG1+ re-
sponders could be visualized independently of BCR density, 
a distinct population of IgG1+ B cells with uniformly in-
creased affi   nity for HEL3X was evident by day 10 of the 
HEL3X-SRBC response and subsequently dominated the 
IgG1+ donor population by day 15 (Fig. 2). This population 
was not apparent at any stage of the response to HELWT-
SRBC (Fig. 2), indicating that the cells were specifi  cally se-
lected because of their increased affi   nity for HEL3X.
To determine whether B cells with high affi   nity for HEL3X 
carry specifi  c somatic mutations that increase their affi   nity for 
HEL3X, single donor-derived GC B cells were sorted from 
immunized mice, and their Ig heavy chain variable region 
genes were sequenced. By day 15 of the response to HEL3X-
SRBC, 82% (23 out of 28) of the clones analyzed carried a 
specifi  c point mutation in the tyrosine 53 codon encoding its 
substitution with aspartate (Y53DHyHEL10; Fig. 3 A). No selec-
tion of any heavy chain mutation was evident in day 15 GC B 
cells produced in response to HELWT-SRBC (Fig. 3 A), which 
was consistent with the proposition that the affi   nity of the 
HELWT–HyHEL10 interaction is too high to permit further 
affi   nity maturation (16). None of the 24 clones analyzed from 
the day 15 HELWT-SRBC GC response contained a mutation 
in the Y53HyHEL10 codon, indicating that the Y53DHyHEL10 
mutation is selected specifi  cally in response to HEL3X-SRBC 
and is therefore likely to increase the affi   nity of HyHEL10 
for HEL3X. This was confi  rmed by sorting high affi   nity anti-
HEL3X IgG1+ donor B cells (see gate in Fig. 2), as subsequent 
sequence analysis revealed that 96% (23 out of 24) of these 
clones carried the Y53DHyHEL10 mutation (unpublished data).
Figure 2.  Tracking affi  nity-based selection in vivo. Splenocytes from 
the response shown in Fig. 1 were analyzed by fl  ow cytometry for their 
expression of CD45.2, IgG1, and the ability to bind the mutant antigen 
HEL3X, and the analogue data are presented on logarithmic axes. The fre-
quency of donor-derived (CD45.2+) cells as a proportion of total spleno-
cytes and the mean fl  uorescence intensity (mfi  ) of HEL3X binding are 
shown. CD45.2+ cells were also analyzed for HEL3X binding counterstained 
against IgG1 (to correct for surface Ig expression level) to show a popula-
tion of high affi  nity HEL3X-binding IgG1+ cells that emerges on day 10 and 
dominates the response to HEL3X-SRBC by day 15 (oval gate). The fre-
quency of these high affi  nity cells as a proportion of donor-derived cells is 
shown. Concatenated data are representative of fi  ve mice in each group.2422  AFFINITY-BASED CONTROL OF PLASMA CELL DIFFERENTIATION | Phan et al.
Analysis of the binding of HEL3X to recombinant wild-
type and Y53D-mutated HyHEL10 IgG1 antibodies showed 
that the Y53DHyHEL10 mutation increases the affi   nity of Hy-
HEL10 for HEL3X by  85-fold (Fig. 3 B). This affi   nity in-
crease was also evident from the ability of the mutated form 
of HyHEL10 to recognize plate-bound HEL3X effi   ciently 
in ELISA under conditions in which binding of wild-type 
HyHEL10 to HEL3X was virtually undetectable (Fig. 3 C). 
Computer modeling revealed that the arginine side chain in-
troduced at position 101 of HEL (D101RHEL) to produce 
HEL3X (14) is likely to cause a major steric confl  ict with the 
phenol group of Y53HyHEL10 and that this confl  ict is resolved 
by the Y53DHyHEL10 substitution (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20061254/DC1).
To examine the selection of the Y53DHyHEL10 mutation 
over the course of the response to HEL3X-SRBC, Ig heavy 
chain gene sequence analysis of single GC B cells and plasma 
cells was performed on days 5, 10, and 15. On day 5, the 
Y53DHyHEL10 mutation was not detectable in either the GC or 
the small plasma cell compartment (Fig. 4 A), which was con-
sistent with the absence of high affi   nity anti-HEL3X B cells at 
this time point (Fig. 2). By day 10, however, this mutation 
was detectable in some GC B cells (22% of sequences) but was 
already present in the great majority of splenic plasma cells 
(86% of sequences). Similar domination of the GC B cell pop-
ulation by this mutation was not evident until day 15 (Fig. 
4 A). Because hypermutated plasma cells must have derived 
from GC B cell precursors, this result shows that GC B cells 
generated in response to HEL3X-SRBC do not undergo sto-
chastic diff  erentiation into plasma cells but instead diff  erentiate 
upon acquisition of the high-affi   nity Y53DHyHEL10 mutation. 
Accordingly, Y53D-mutated clones that had left the GC and 
diff  erentiated into plasma cells by day 10 of the response had a 
signifi  cantly lower overall rate of SHM than the Y53D-mu-
tated clones that remained within the GC compartment (2.2 
vs. 4.6 mutations/clone, respectively; P = 0.02).
To monitor affi   nity-based regulation of post-GC plasma 
cell diff  erentiation more directly, we next challenged donor B 
cells from SWHEL  ×  Blimpgfp/+ mice with HEL3X-SRBC. 
Plasma cells generated in Blimpgfp/+ mice express GFP under 
the control of the Blimp-1 promoter and, thus, can be detected 
via intrinsic green fl  uorescence (17). By using SWHEL × Blimpgfp/+ 
donor B cells in conjunction with our method for identi-
fying somatically mutated B cells with high affi   nity for HEL3X 
(Fig. 2), we directly assessed the antigen affi   nity of post-GC 
IgG1+ plasma cells in the spleen. Analysis of GFP expression 
by low and high affi   nity donor-derived IgG1+ B cells on day 
10 of the response to HEL3X-SRBC clearly demonstrated that 
GFP-expressing plasma cells originated almost exclusively from 
GC precursors that had acquired a high affi   nity anti-HEL3X 
BCR (2.54% of high affi   nity compared with 0.27% of low af-
fi  nity cells; Fig. 4 B). These GFP+ cells also had low but de-
tectable levels of surface CD45.2 and IgG1 (Fig. 4 B and not 
depicted), as is typical of plasma cells (14). Because >95% of 
high affi     nity clones detected by HEL3X binding have the 
Y53DHyHEL10 mutation, most of these GFP+ plasma cells are 
likely to secrete antibodies carrying this amino acid change. 
Indeed, the serum IgG1 found in mice challenged with HEL3X-
SRBC shows almost identical antigen-binding characteristics 
to Y53D-mutated HyHEL10 (Fig. 1 D and Fig. 3 C).
The model system described in this report provides a 
unique window into the GC reaction by allowing the ap-
pearance, selection, and diff  erentiation of high affi   nity so-
matically mutated B cells to be followed throughout the 
response. We have used this system to demonstrate that high 
affi   nity B cell specifi  cities generated within the GC are har-
nessed to drive affi   nity maturation of the antibody response 
Figure 3.  Selection of a high affi  nity Y53D somatic mutation in 
response to HEL3X-SRBC. (A) SHM analysis of targeted Ig heavy chain loci 
of responding SWHEL GC B cells was performed on day 15 of the responses to 
HELWT-SRBC and HEL3X-SRBC, as described in Materials and methods. The 
codon encoding Y53 was found to be extensively mutated in the HEL3X-SRBC 
response (86% of sequences) and replaced by an aspartate residue (Y53D) in 
the majority (82%) of cases. (B) ELISA showing the binding of soluble HEL3X 
to plate-bound recombinant wild-type (HyHEL10WT) and Y53D-mutated 
(HyHEL10Y53D) HyHEL10 IgG1 antibodies. The Y53D mutation increased the 
affi  nity of HyHEL10 for HEL3X by  85-fold. (C) ELISAs showing the relative 
binding of soluble recombinant HyHEL10WT and HyHEL10Y53D antibodies to 
plate-bound HELWT versus HEL3X. All four binding assays were run in parallel.JEM VOL. 203, October 30, 2006  2423
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by a mechanism that ensures their rapid and selective diff  er-
entiation into plasma cells.
Because low affi   nity B cells survive within GCs without 
undergoing plasma cell diff  erentiation (Fig. 4 B), it is apparent 
that the affi   nity-dependent mechanism that regulates plasma 
cell diff  erentiation from GC B cell precursors operates inde-
pendently of the processes that govern GC B cell survival. The 
existence of this mechanism was not predicted from in vitro 
experiments, because these show that B cells can undergo sto-
chastic plasma cell diff  erentiation without   requiring a BCR 
signal (9). This would suggest that specifi  c controls exist within 
the GC microenvironment that suppress plasma cell diff  eren-
tiation in the absence of signals from high affi   nity antigen.
The requirement for antigen-dependent signals to drive 
plasma cell diff  erentiation from GC B cells presents an inter-
esting parallel with the regulation of the extrafollicular plasma 
cell response. These early plasma cells arise independently of 
the GC reaction (3) but are similarly biased toward high affi   n-
ity specifi  cities or epitopes present at high density (14). There-
fore, the BCR–antigen interaction appears to play a key role 
in regulating TD plasma cell diff  erentiation both before and 
after GC formation. It is possible that BCR signaling could 
facilitate plasma cell diff  erentiation via the induction of Bcl-6 
degradation (18) and subsequent lifting of Blimp-1 repres-
sion (19). Alternatively, responding B cells may stochastically 
commence plasma cell diff  erentiation but require BCR sig-
nals to survive beyond the very earliest stages of this process. 
Whatever the precise mechanism, it is apparent that the im-
mune system places a high priority on ensuring that it devotes 
resources primarily to the production of relatively high affi   n-
ity antibodies that are most likely to be biologically eff  ective. 
The importance of this stringent regulation of plasma cell dif-
ferentiation is perhaps underscored by the relatively permis-
sive affi   nity requirements for GC B cells to enter the memory 
B cell compartment (10, 20). The emphasis on quality control 
of in vivo plasma cell diff  erentiation may have been a critical 
development during the evolution of the immune system. 
Because the body is known to have only a relatively limited 
capacity within the specialized microenvironments that sus-
tain plasma cells (21, 22), it can be seen that tight control over 
the specifi  cities that enter the plasma cell compartment would 
be essential for ensuring that the antibodies that are produced 
provide eff  ective immune protection.
MATERIALS AND METHODS
Mice and procedures. SWHEL mice (13), Blimpgfp/+ mice (17), mutant 
HEL proteins (14), conjugation of HEL to SRBC, and the adoptive transfer 
system (12) have been previously described. SWHEL spleen cells were not 
purifi  ed before transfer. Mice were housed in a specifi  c pathogen-free envi-
ronment at Centenary Institute, and experiments were approved by the 
University of Sydney Animal Ethics Committee.
ELISA. Serum anti-HEL antibody levels were analyzed by ELISA as previ-
ously described (13). The specifi  city of serum IgG1 antibodies for HELWT 
Figure 4.  Affi  nity threshold for post-GC plasma cell differentia-
tion. (A) SWHEL B cells were adoptively transferred and challenged with 
HEL3X-SRBC, and individual donor-derived GC B cells and plasma cells 
were sorted for SHM analysis, as described in Materials and methods. 
The proportion of donor-derived GC B cells and plasma cells with the 
Y53DHyHEL10 mutation on days 5, 10, and 15 of the response are shown. 
From left to right, SHM frequencies were 28, 1, 98, 61, 137, and 157 
mutations per 104 bp. (B) SWHEL B cells with (SWHEL × Blimpgfp/+) and 
without the Blimp-GFP reporter gene were adoptively transferred and 
challenged with HEL3X-SRBC as in Fig. 1. Splenocytes harvested on day 
10 were analyzed by flow cytometry for expression of GFP, CD45.2, 
IgG1, and HEL3X binding, and digital data are presented using biexponen-
tial axes. (left) Plots show HEL3X binding versus IgG1 gated on CD45.2+ 
donor-derived cells. (right) GFP expression by high (top oval gate) and 
low (bottom oval gate) affi  nity cells are shown. A distinct population 
of Blimp-GFP–expressing plasma cells is only evident in high affi  nity 
cells in mice that received SWHEL × Blimpgfp/+ B cells. Profi  les represent 
concatenated data with equal contributions from fi  ve individual recipi-
ent mice. Similar results were obtained in two independent experiments.2424  AFFINITY-BASED CONTROL OF PLASMA CELL DIFFERENTIATION | Phan et al.
and HEL3X was determined by coating the ELISA plates with the respec-
tive antigens. The relative affi   nities of HyHEL10WT and HyHEL10Y53D for 
HEL3X were determined by capture ELISA. 5 μg/ml each of soluble Hy-
HEL10WT and HyHEL10Y53D IgG1 antibodies was captured by plate-bound 
anti–mouse IgG1. Subsequent binding of HEL3X was detected with biotin-
ylated HyHEL9, which recognizes an epitope on HEL distinct from that 
bound by HyHEL10. Nonlinear regression based on a sigmoidal binding 
curve was performed using software (Prism; GraphPad) to fi  nd the curve-fi  t 
and calculate the half-maximal binding concentration and relative affi   nity of 
HyHEL10WT and HyHEL10Y53D for HEL3X.
Flow cytometry and single cell sorting. Splenocytes were prepared, 
stained for surface molecules with monoclonal antibodies, and analyzed 
on a FACSCalibur (BD Biosciences) as previously described (14). To track 
affi   nity maturation, cells were stained with recombinant HEL3X conjugated 
to Alexa Fluor 647 (Invitrogen). For analysis of Blimp-GFP expression, 
CD45.2 was conjugated to Pacifi  c blue (Invitrogen) to allow identifi  cation 
of donor-derived cells and data acquired on a fl  ow cytometer (LSR II; BD 
Biosciences). Single cells were sorted on a FACSAria (BD Biosciences) as 
previously described (14). The gates used for single cell sorting of GC B cells 
(CD45.2hi, syndecan-1−) and plasma cells (CD45.2int, syndecan-1+) were 
the same as those previously described (14). These gates have been verifi  ed 
through   localization of antibody secreting activity (12) and high levels of in-
tracellular Ig staining (14) to cells in the plasma cell gate and demonstration 
of high   levels of GL7, PNA, and Fas on cells in the GC gate (12, 14).
SHM analysis. The HyHEL10 Ig heavy chain variable region gene was 
amplifi  ed from single-responding SWHEL donor B cells and sequenced as 
previously described (14). Translated sequences were aligned with the origi-
nal HyHEL10 protein sequence to determine the position and signifi  cance 
of the mutations, as previously described (12). An unpaired t test was used to 
calculate the probability (p-value) when comparing SHM frequency per 
clone in diff  erent responding populations.
Expression of wild-type and Y53D-mutated HyHEL10 IgG1 anti-
bodies. The canonical T to G mutation encoding the Y53DHyHEL10 substi-
tution was introduced by PCR mutagenesis into a pcDNA3 vector 
(Invitrogen) encoding the HyHEL10 γ1-secreted Ig heavy chain. Wild-type 
and mutant heavy chain constructs were transiently expressed in Chinese 
hamster ovary cells along with wild-type HyHEL10 κ light chain construct, 
and culture supernatants were collected and concentrated.
Online supplemental material. Fig. S1 shows Rasmol wire frame rep-
resentations based on the HEL–HyHEL10 complex that model the eff  ects 
of the D101RHEL and Y53DHyHEL10 substitutions on the interaction. On-
line supplemental material is available at http://www.jem.org/cgi/content/
full/jem.20061254/DC1.
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